Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11988941 | 0.85 | CES2 (0.58) | CES2CES1LCKFYNDAO | |
| SCHEMBL28587407 | 0.77 | CES2 (0.48) | CES2CES1LCKFYNDAO | |
| SCHEMBL12431216 | 0.77 | CES2 (0.58) | CES2CES1LCKFYNDAO | |
| SCHEMBL8614179 | 0.77 | CES1 (0.58) | CES2CES1LCKFYNDAO | |
| SCHEMBL10425 | 0.73 | — | — | |
| SCHEMBL4876161 | 0.72 | — | — | |
| SCHEMBL228306 | 0.72 | — | — | |
| SCHEMBL2166098 | 0.72 | CES2 (0.71) | CES2CES1LCKFYNDAO | |
| SCHEMBL8182714 | 0.72 | CES2 (1.00) | CES2CES1LCKFYNDAO | |
| SCHEMBL27536114 | 0.72 | CES2 (0.52) | CES2CES1LCKFYNDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093241-B2 | Acid amide derivatives, process for their production and pesticides containing them | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20100093707-A1 | ACID AMIDE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PESTICIDES CONTAINING THEM | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-7683096-B2 | Acid amide derivatives, process for producing these, and pest control agent containing these | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20040254237-A1 | Acid amide derivatives, process for producing these, and pest agent containing these | ISHIHARA SANGYO KAISHA LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1428817-A1 | ACID AMIDE DERIVATIVES, PROCESS FOR PRODUCING THESE, AND PEST CONTROL AGENT CONTAINING THESE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093707-A1 | ACID AMIDE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PESTICIDES CONTAINING THEM | NAA15, SAP18, CYP2C18 | CES2 646/4885CES1 593/4885LCK 3746/4885 |
| US-20040254237-A1 | Acid amide derivatives, process for producing these, and pest agent containing these | NAA15, CBR3, CBR1 | CES2 744/4885CES1 729/4885LCK 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.